AtriCure (ATRC) Reports In-Line Q3 EPS; Guides FY15 Revenue Above Consensus

AtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $31.4 million versus the consensus estimate of $31.38 million.

AtriCure sees FY2015 revenue of $129.5-130.5 million, versus the consensus of $128.6 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c